Ori Biotech: The Cambridge Startup Solving Cell Therapy's Manufacturing Crisis

Back to: Top 10 British Startups 2026

The promise of cell and gene therapy has been visible to scientists for decades: the ability to engineer living cells to attack cancer, correct genetic defects, and restore function to tissues and organs damaged by disease. That promise has been progressively validated by a series of clinical breakthroughs — CAR-T cell therapies that produce durable remissions in blood cancers, gene therapies that restore sight to patients with inherited blindness, RNA therapies that silence disease-causing genes. But the industrial infrastructure to manufacture these treatments at the scale needed to serve the patients who need them has lagged far behind the clinical science. Ori Biotech, a Cambridge company, is building that infrastructure.

Company Overview

Ori Biotech was founded in 2019 by Jonathan Bones and Raman Sehgal, both veterans of the cell and gene therapy manufacturing sector with direct experience of the bottlenecks and inefficiencies that prevent these treatments from reaching patients at scale. The company's core product is an automated, closed-system manufacturing platform that replaces the labour-intensive, open-process techniques currently used to produce most cell and gene therapies. By automating and standardising the manufacturing process, Ori makes it possible to produce more therapies, more consistently, at lower cost and with reduced risk of contamination.

The company has raised $100 million from a combination of venture capital firms and strategic investors including manufacturing equipment providers and pharmaceutical companies with significant cell therapy pipelines. This funding has supported the development and commercial launch of the IPS platform — an integrated, automated system designed to be the foundation of next-generation cell therapy manufacturing facilities worldwide.

Business Model

Ori Biotech sells its manufacturing platform to cell and gene therapy developers — pharmaceutical companies and specialist biotech firms with therapy candidates in clinical development or commercial launch. Revenue comes from platform sales, which include both the hardware and software components of the IPS system, as well as ongoing service contracts covering maintenance, consumables, and software updates. The company also generates revenue from development services, helping clients optimise their manufacturing processes for the IPS platform.

The recurring revenue component of Ori's business model is particularly attractive from an investor perspective. Once an IPS system is installed in a therapy developer's manufacturing facility and integrated into their quality management systems, the switching costs are very high — creating a long-term recurring revenue relationship that should persist for the operational life of the system, which is measured in decades rather than years.

Innovation Factor

The manufacturing of living cell therapies is fundamentally different from the manufacturing of conventional drugs or biologics. Unlike a small molecule drug that can be synthesised through a chemical process or a protein biologic that can be produced in bioreactors using established fermentation technology, cell therapies require the handling of living human cells through a series of complex biological processes — expansion, activation, genetic modification, selection, and formulation — each of which must be performed under precisely controlled conditions to maintain cell viability and therapeutic potency.

Ori's IPS platform addresses this complexity through a combination of advanced bioreactor design, integrated process monitoring, automated fluid handling, and intelligent process control software that maintains optimal conditions throughout the manufacturing run. The closed-system design minimises contamination risk by eliminating the open-process steps that represent the primary contamination hazard in conventional manufacturing. And the automation of previously manual steps not only improves consistency but reduces the highly skilled labour requirements that make conventional cell therapy manufacturing so expensive to scale.

Market Position

Ori Biotech is one of a small number of companies globally addressing the cell and gene therapy manufacturing bottleneck, but its combination of technical maturity, commercial traction, and Cambridge-based talent pipeline gives it a strong competitive position. The market opportunity is substantial: the global cell and gene therapy market is forecast to exceed $30 billion by 2030, and manufacturing capacity is widely identified as the primary constraint on market growth. See also: Healx's AI drug discovery and Faculty AI's NHS partnerships.

What's Next

Ori Biotech is working to expand its platform's capabilities to support a broader range of cell and gene therapy types, including allogeneic — off-the-shelf — therapies that represent the next wave of commercial development in the sector. Partnerships with therapy developers advancing through late-stage clinical trials represent the most immediate commercial opportunity, as these companies face imminent manufacturing scale-up challenges that Ori's platform is designed to address. Visit oribiotech.com for more.